Credit Suisse’s Meridian Bioscience Inc VIVO Stock Holding History

Credit Suisse’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-100,000	Closed	-$2.05M	–	4369
2015 Q4	$2.05M	Hold	100,000	–	–	﹤0.01%	2258
2015 Q3	$1.71M	Buy	+100,000	New	+$1.83M	﹤0.01%	2372

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's VIVO Position: Q1 2023 in Review

Credit Suisse sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 134,566 shares — an estimated $4.47M sold.

Credit Suisse first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $4.47M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Credit Suisse reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 134,566 Meridian Bioscience Inc shares in Q1 2023, an estimated $4.47M.
Credit Suisse first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
Credit Suisse's Meridian Bioscience Inc position peaked at $4.47M in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.